Genetics of arrhythmogenic right ventricular cardiomyopathy
Óscar Campuzano(Universitat de Girona), Ramón Brugada(Institut d'Investigació Biomèdica de Girona), Pedro Brugada(Onze Lieve Vrouwziekenhuis Hospital), Josép Brugada(Hospital Clínic de Barcelona), Catarina Allegue(Universitat de Girona), Pablo García‐Pavía(Universidad Francisco de Vitoria), Anna Iglesias(Universitat de Girona), Paola Berne(University of Sassari), Mireia Alcalde(Institut d'Investigació Biomèdica de Girona), Sara Partemi(Università Cattolica del Sacro Cuore), Georgia Sarquella‐Brugada(Hospital Sant Joan de Déu Barcelona), Vincenzo L. Pascali(Università Cattolica del Sacro Cuore), Antonio Oliva(Università Cattolica del Sacro Cuore)
Cited by 56
Related Papers
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
|Heart Rhythm|2017|2.7k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
|EP Europace|2017|1.2k
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
|European Heart Journal|2015|1.1k